Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment